202 related articles for article (PubMed ID: 29228059)
1. Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients.
Rohner E; Grabik M; Tonia T; Jüni P; Pétavy F; Pignatti F; Bohlius J
PLoS One; 2017; 12(12):e0189309. PubMed ID: 29228059
[TBL] [Abstract][Full Text] [Related]
2. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data.
Bohlius J; Tonia T; Nüesch E; Jüni P; Fey MF; Egger M; Bernhard J
Br J Cancer; 2014 Jul; 111(1):33-45. PubMed ID: 24743705
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R; Wao H; Miladinovic B; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009624. PubMed ID: 26845108
[TBL] [Abstract][Full Text] [Related]
5. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
[TBL] [Abstract][Full Text] [Related]
7. Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review.
Paludan-Müller AS; Créquit P; Boutron I
BMC Med; 2021 Apr; 19(1):88. PubMed ID: 33827569
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
Musini VM; Lawrence KA; Fortin PM; Bassett K; Wright JM
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007066. PubMed ID: 28379619
[TBL] [Abstract][Full Text] [Related]
9. European Medicines Agency Policy 0070: an exploratory review of data utility in clinical study reports for academic research.
Ferran JM; Nevitt SJ
BMC Med Res Methodol; 2019 Nov; 19(1):204. PubMed ID: 31690260
[TBL] [Abstract][Full Text] [Related]
10. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
[TBL] [Abstract][Full Text] [Related]
11. Harms of off-label erythropoiesis-stimulating agents for critically ill people.
Mesgarpour B; Heidinger BH; Roth D; Schmitz S; Walsh CD; Herkner H
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010969. PubMed ID: 28841235
[TBL] [Abstract][Full Text] [Related]
12. Access to regulatory data from the European Medicines Agency: the times they are a-changing.
Wieseler B; McGauran N; Kerekes MF; Kaiser T
Syst Rev; 2012 Oct; 1():50. PubMed ID: 23110993
[TBL] [Abstract][Full Text] [Related]
13. Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents.
Tonia T; Schwarzer G; Bohlius J
Swiss Med Wkly; 2013; 143():w13776. PubMed ID: 23740272
[TBL] [Abstract][Full Text] [Related]
14. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis-stimulating agents in gynecological malignancies: A study-level meta-analysis.
Marchetti C; De Felice F; Palaia I; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2016 Mar; 99():123-8. PubMed ID: 26748593
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin or darbepoetin for patients with cancer.
Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
[TBL] [Abstract][Full Text] [Related]
17. Ten years of meta-analyses on erythropoiesis-stimulating agents in cancer patients.
Tonia T; Bohlius J
Cancer Treat Res; 2011; 157():217-38. PubMed ID: 21052959
[TBL] [Abstract][Full Text] [Related]
18. Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.
Gao S; Ma JJ; Lu C
Tumour Biol; 2014 Jan; 35(1):603-13. PubMed ID: 23959477
[TBL] [Abstract][Full Text] [Related]
19. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
Wilson J; Yao GL; Raftery J; Bohlius J; Brunskill S; Sandercock J; Bayliss S; Moss P; Stanworth S; Hyde C
Health Technol Assess; 2007 Apr; 11(13):1-202, iii-iv. PubMed ID: 17408534
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]